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Abstract: 24 
Setting: Pakistan ranks fourth among high multi-drug resistance tuberculosis burden countries 25 
with only 19.2% of the 15,000 estimated incident cases being notified. Increasing treatment 26 
coverage for multi-drug resistance tuberculosis is a key priority for National Tuberculosis 27 
Program in Pakistan. World Health Organization recommends the use of Xpert MTB/RIF® 28 
assay as the first-line diagnostic test for individuals with presumed tuberculosis.  29 
Objective: To describe a multi-faceted case-finding intervention targetting the public and private 30 
sectors that utilized Xpert MTB/RIF as a frontline diagnostic test for individuals with 31 
presumptive tuberculosis, in Karachi, Pakistan, and its impact on case-notifications of multi-drug 32 
resistance tuberculosis.  33 
Design: Cross sectional study  34 
Results: A total of 51,168 were tested on Xpert MTB/RIF®, of which 7,581 and 1,534  people 35 
were diagnosed with TB in the public sector (Reverse-Public private mix) and private sector 36 
(Social business model) arms, respectively, 574 (6.3% of all TB cases) were identified with 37 
Rifampicin resistance. A total of 517 (90.1%) people with rifampicin resistant tuberculosis, 38 
identified through the project were initiated on second-line treatment. The intervention resulted 39 
in 194 additional cases of rifampicin resistant tuberculosis, an increase of 43% over the baseline. 40 
Conclusion: This project, one of the largest Xpert MTB/RIF® testing programs conducted at a 41 
city level, resulted in significantly increased detection and treatment of multi-drug resistance 42 
tuberculosis.  43 
 44 
 45 
 46 
47 
Introduction: 48 
Multi-drug resistant tuberculosis (MDR-TB) represents a significant threat to the ambitious 49 
global targets for ending TB [1,2]. In 2016, out of the estimated 490,000 people developing 50 
MDR-TB, only 153,119 (31.2%) were diagnosed and 129,689 (26.4%) were enrolled on second 51 
line treatment, and reported (Global report 2017) [2]. For many years, inadequate diagnostic 52 
capacity, particularly the limited availability of sensitive rapid diagnostic tests has been a key 53 
constraint [3]. The World Health Organization (WHO) currently recommends the use of Xpert 54 
MTB/RIF®(Xpert) assay as the first-line diagnostic test for individuals with presumed TB 55 
[Meeting Report 4]. While South Africa witnessed large increases in the numbers of people 56 
detected with drug resistance by using Xpert as the initial diagnostic test [5], many countries 57 
have used restrictive algorithms primarily due to high costs, relative to conventional smear 58 
microscopy [6] where limiting testing to previously treated patients and those with other risk 59 
factors misses out on MDR-TB among the large numbers of incident TB cases [7]. 60 
Pakistan has the fourth highest burden of MDR-TB globally [2]. Increasing treatment coverage 61 
for MDR-TB forms an integral part of the National Strategic Plan for TB in Pakistan [8]. 62 
However, of an estimated of 15,000 incident MDR-TB cases, only 2,881 (19.2%)(country 63 
profile) were enrolled for treatment in 2016, highlighting a significant treatment coverage gap 64 
[2]. Up to 90% of the MDR-TB burden is among people without known history of previous anti-65 
TB treatment and are not currently covered through routine drug susceptibility testing (DST) [3]. 66 
While the absolute number of MDR-TB cases is high, the prevalence of MDR-TB among both 67 
new (4.2%) and retreatment cases (16%) in Pakistan is low, relative to other high MDR-TB 68 
burden countries in Eastern Europe and Central Asia [2].(Pakistan’s only drug resistance survey 69 
was conducted in 2012-2013). To find additional cases of MDR-TB, testing on a large pool of 70 
people is required which may be resource intensive [9]. Additionally, in Pakistan, three-quarters 71 
of the population accesses healthcare through the private-sector [10]. However, the Public 72 
Private Mix (PPM) contribution to TB case notification was 28% in 2016 , (global report 2017), 73 
previous efforts to form linkages with private-providers for drug-susceptible TB have not 74 
focused on detection of MDR-TB. Xpert testing in the private sector without donor or 75 
government subsidies is prohibitively expensive for most patients [11].  76 
The Xpert assay was introduced in Pakistan in 2011[3]. However, further experience in scaled 77 
implementation of Xpert testing is required to inform its utilization across the different levels of 78 
the health system. This study describes a multi-faceted case-finding intervention targetting the 79 
public and private sectors that utilized Xpert as a frontline diagnostic test in Karachi, Pakistan, 80 
and its impact on case-notifications of drug resistant tuberculosis (DR-TB). We aim to fill the 81 
gaps in published literature on potential constraints in implementation of Xpert testing in high 82 
MDR burden, programmatic settings. 83 
 84 
Study Population and Methods: 85 
Study setting 86 
Karachi is the country’s largest city and economic hub, with a population estimated of 23 million 87 
[12] with over 60% of the population residing in high-density slums [10]. Approximately 15 88 
private-sector facilities are registered as Basic Management Units (BMUs) with the NTP where 89 
TB diagnostic and treatment services are available. A total of 3 programmatic management for 90 
drug-resistant TB  (PMDT) sites (two in the public-sector, one private-sector), are present in the 91 
city where patients can receive MDR-TB treatment, offered free-of-cost.  92 
Project Interventions 93 
This project was part of the TBXpert Project that aimed to increase case-notification for TB 94 
through scale-up of Xpert testing. The intervention in Karachi consisted of two distinct arms: 1) 95 
a Reverse - Public Private Mix (R-PPM) arm, targeting public-sector hospitals and Programmatic 96 
Management of Drug Resistant Tuberculosis (PMDT) sites; and 2) a Social Business Model 97 
(SBM) targeting the private-sector. A new case was defined as not having been treated for TB 98 
previously. 99 
 100 
Reverse Public-Private Mix (R-PPM) Model: 101 
Under this approach, TB diagnostics and treatment capacity was strengthened at exiting public-sector 102 
facilities. Xpert machines were installed at the TB laboratories of 6 public-sector hospitals and 1 103 
private-sector PMDT site. The hospitals were provided additional staff including an Xpert technician 104 
and health workers who screened individuals in waiting areas of outpatient clinics and other wards 105 
of the hospitals for TB symptoms, as per the WHO symptom screen (ref) including cough of any 106 
duration, fever, hemoptysis, night-sweats and unexplained weight-loss. The health workers also 107 
supported the TB clinic through collection of sputum samples from other wards, assisting patients in 108 
sputum expectoration, data collection, registering and counseling of people with TB. Sputum was 109 
collected for Xpert testing from all presumptives who were able to expectorate sputum and gave 110 
consent for the test. The intervention sites were set targets for TB case-identification and 111 
compensation for staff was performance-based, with incentives provided for TB case-identification 112 
and ensuring high treatment initiation rates. Supervisory visits by managers were carried out to ensure 113 
maintenance of equipment, quality assurance of data, trouble-shooting and ensuring supply-chain of 114 
Xpert cartridges was appropriately maintained.  115 
 116 
Social Business Model (SBM) 117 
TB testing was carried out at three purpose-built TB centers called “Sehatmand Zindagi” 118 
(Healthy Life). This model utilized community-based screeners, placed at 180 private health 119 
providers’ clinics (including both formal and informal) in the vicinity of the TB centers where 120 
they carried out verbal symptomatic screening (as per the WHO symptom screen) of patients and 121 
referred them for testing that is a Chest X-ray (US$3-5) and free-of-cost Xpert at the centers after 122 
a positive symptom screen and clinical evaluation by the health providers. Those individuals who 123 
could not pay for the chest Xray, were cascaded directly to Xpert while those who were unable to 124 
expectorate sputum for testing were further evaluated by a clinical officer based on clinical 125 
symptoms and chest Xray findings. The SBM intervention evolved towards developing a 126 
medical detailing team, that engaged a network of approximately 600 private-providers and 127 
encouraged referrals for TB testing. People identified with drug-susceptible TB in the SBM 128 
intervention were provided free treatment from the centers, registered as BMUs with the 129 
Provincial Tuberculosis Program (PTP). People at R-PPM sites were registered for treatment at 130 
the testing site or at the facility of referral. Individuals identified with rifampicin resistance(Rif-131 
resistance) were referred to the one of the three PMDT sites in the city and initiated on second-132 
line drugs, after repeat Xpert testing.  Sputum samples were also obtained for culture from all 133 
patients registered for treatment for confirmation of Rif resistance. 134 
 135 
Data Analysis:  136 
The study utilized de-identified data collected for patient screening and testing indicators including 137 
Xpert log files and summary of laboratory reports from each intervention site, for a total time-138 
period of 8 quarters of the intervention from Q3-2013 – Q2 2015. Aggregate summary reports for 139 
quarterly patient enrollment and treatment initiation at PMDT sites was obtained to identify the 140 
total number of Rif resistant TB cases registered in Karachi.  141 
Summary statistics describing Xpert testing and Mycobacterium TB (MTB) yield at each 142 
intervention site and intervention (SBM and R-PPM) were determined. The TB REACH 143 
methodology for additionality calculations was adapted for DR-TB notifications [13]. This 144 
approach allows for a more accurate estimation of impact directly attributable to project activities. 145 
Briefly, the methodology involves determining the quarterly historical case-notifications in the 146 
intervention area of the previous 12 quarters prior to the start of the activities. A regression line is 147 
fitted to the historical notifications and extrapolated to forecast notifications that would have taken 148 
place in the absence of any intervention. These are compared with the number of actual 149 
notifications that took place during the intervention period to determine the overall additionality 150 
of cases. In order to control any bias resulting from the setup of new PMDT sites outside of 151 
Karachi, cases were known to have residential addresses outside of the city, were excluded from 152 
the analysis. All data analysis was carried out on Microsoft Excel. 153 
 154 
Ethical Approval: 155 
This study was approved by the Institutional Review Board (IRB) at Interactive Research and 156 
Development (IRD). The IRB is registered with the U.S. Department of Health and Human 157 
Services (DHHS), Office for Human Research Protections (IRB#00005148). 158 
Verbal consent was obtained from participants before conducting Xpert tests.  159 
 160 
Results: 161 
TB Screening and Xpert MTB/RIF testing: 162 
Between July 2013 and June 2015, 115,360 people with presumptive TB were identified, 80.4% 163 
through the R-PPM intervention and 19.6% through the SBM (Figure 1). Of these 39 301clients 164 
at the R-PPM sites and 11 867 clients at the SBM sites had Xpert tests performed (Figure 1). A 165 
total of 9,115 MTB+ cases were detected through the two interventions; 7,581 (83.2%) and 1 534 166 
(16.8%) MTB+ cases were identified in the R-PPM and SBM arms, respectively. Yield of 167 
bacteriologically positive cases was 19.3% at R-PPM sites and 12.9% at the SBM sites. Table 1 168 
shows the difference in Xpert testing, cases detected and started on treatment, between the two 169 
intervention arms. 170 
 171 
DR-TB treatment coverage: 172 
Of all MTB+ individuals, 8,541(93.7%) were drug susceptible, of whom 7,576 started on first 173 
line treatment (88.7% of the total). Among those with a MTB+ result, 574 (6.3%), were also 174 
identified with Rif-resistance (Rif+/DR-TB), of whom 524 (91.3%) were detected at the R-PPM 175 
sites and 50 (8.7%) at the SBM sites. The yield of Rif-resistance was 6.9% and 3.3% for R-PPM 176 
and SBM interventions, respectively (Figure 1). Within the Rif+ (presumed and confirmed Rif-177 
resistance) identified through the project, a total of 517 were initiated on second-line treatment 178 
(90.1% of the total yield). A total of 46 (8.5%) individuals were pre-treatment loss to follow-up, 179 
whereas 11 (2.1%) deaths were recorded.  180 
 181 
Impact on notified DR-TB cases in the intervention population (Karachi district) 182 
At the Karachi district level, a total of 642 DR-TB cases were detected during the intervention 183 
period of which 149 were new diagnoses. This constituted a 43% increase in identification of DR-184 
TB cases over the baseline trend (Figure 2). The proportion of newly diagnosed cases among all 185 
reported DR-TB cases increased from 7% in Q2 2013 to 22% in Q2 2015 during the intervention 186 
period (Figure 3) 187 
 188 
Discussion: 189 
This is the first study to investigate the impact of scaling Xpert implementation on additional DR-190 
TB case-notifications from a programmatic setting in Pakistan. Our intervention targeted both the 191 
public, and the private sector through an innovative social business approach, distinguishing it 192 
from other studies reported from high MDR-TB burden countries.  193 
An increase in number of DR-TB cases notifications in Karachi was observed relative to the years 194 
prior to the intervention. This study therefore supports existing evidence from other programmatic 195 
settings that have reported up to eight-fold increase in Rif resistant-TB case-detection through 196 
upfront Xpert testing [14-18]. Xpert testing has increased access to DST in countries such as South 197 
Africa, where up to 65% of new cases and 71% of previously treated cases have been tested for 198 
Rif-resistance [2], exceeding previous prevalence estimates for the disease in the country [2].  199 
This study provides a number of lessons that can inform scale-up of Xpert in Pakistan and 200 
elsewhere. Our study highlights the significance of employing both, active case finding approaches 201 
and expanded diagnostic algorithms for Xpert testing to bridge the case-detection gap for DR-TB.  202 
Since new cases comprise up to 97% of the total TB cases notified, the burden of DR-TB is 203 
overwhelmingly within this group that does not receive routine access to DST [2]. In our study, 204 
the proportion of newly diagnosed cases among DR-TB cases increased from 7% at baseline to 205 
22%. However, the estimates for MDR-TB among new cases are much higher, and further scale-206 
up of Xpert testing is expected to achieve greater yields. 207 
Operationally, treatment initiation of patients diagnosed with Rif-resistance may be challenging 208 
[19-21]. Figure 4 summarizes factors that have contributed to low enrollment of patients in MDR-209 
TB treatment program in Pakistan. The additional human resource provided at the TB centers in 210 
the private and public-sector hospitals that worked to support linkages to PMDT sites, 211 
complimented by close collaboration with PTP, resulted in a high proportion Rif-resistance cases 212 
to be initiated on treatment, with only 8.5% pre-treatment loss to follow-up in the project. It is 213 
important that future scale-ups invest in data systems, human resource training and strengthening 214 
linkages to DR-TB treatment sites, to ensure treatment initiation and better outcomes for 215 
individuals with DR-TB. 216 
The R-PPM intervention involved fewer human and infrastructural investments in comparison to 217 
the private-sector intervention. The public sector sites carrying out the project interventions were 218 
high volume tertiary care hospitals, providing a large population base to screen from. Four-fifths 219 
of all Xpert tests were carried out through the R-PPM intervention. A higher MTB+ rate (MTB+ve 220 
out of all those tested) of 19.3% was also observed compared to SBM (12.9%) and it detected over 221 
90% of all Rif-resistant cases in the project. We hypothesize that sicker individuals are found at 222 
tertiary care hospitals compared to GP clinics leading to higher MTB+ and Rif+ yields at these 223 
sites. Our experience, therefore, supports targeted approaches such as R-PPM that leverage 224 
existing infrastructure and carryout structural enhancements and process improvements to increase 225 
access to DST. The private-sector intervention utilized a novel approach to PPM by establishment 226 
of new health centers and a referral network of private-providers through a sustainable social 227 
business model.  While the SBM approach only detected 16.8% of all MTB+ cases and 50 Rif-228 
resistant in the project cases, the number of referrals and Rif-resistant cases identified in the private 229 
sector increased over the course of the project and were less likely to be detected in the public 230 
sector. Comparable trends are experienced in the establishment of any new business, where 231 
generating “foot-fall” often takes significant time before reaching maturity [22]. Similar strategies 232 
may be considered in countries with a rampant private health sector, particularly in South-Asia 233 
and Africa. While about three-quarters of all health services are availed in the private sector in 234 
Pakistan [10,11], only 28% of all TB cases were notified through private facilities [2]. During the 235 
study period the PPM contribution to TB case notifications was 15-20% in Pakistan and varied 236 
between 13-17% in India and about 55% in China (global report 2017). Increased engagement 237 
with the private-sector is therefore necessary despite lower yields and higher costs to identify 238 
additional cases that would likely have otherwise remained undiagnosed [1,2].  239 
The potential options for diagnostic algorithms and case finding strategies need to be carefully 240 
appraised and measured against cost implications for each setting. Of the 48 high burden countries, 241 
at least 15 have adopted national guidelines based on testing of all presumptive TB cases on Xpert 242 
[2]. This may not be feasible in resource-constrained settings, including for countries with donor 243 
support for TB programs. However, testing algorithms focused on drug resistance presumptives 244 
only, may limit case-detection as a significant number of MDR-TB cases are among new TB cases. 245 
Pakistan’s first national anti-tuberculosis drug resistance survey reported Rif-resistance in 4.4% 246 
(95% CI: 2.4–4.9) of new cases [23]. Application of novel screening tools such as digital chest x-247 
rays with computer-aided detection (CAD) has the potential to save Xpert cartridges and 248 
consequentially save costs [24, 25].  249 
In our study, Xpert testing could only be performed on less than half of people identified as needing 250 
testing. Support was provided for expectoration through nebulizers and mucolytic agents, incurred 251 
additional costs and patient counseling efforts. Similar challenges may be encountered in other 252 
active case finding programs. Our experience with technical issues and equipment malfunctions is 253 
consistent with those reported by early Xpert implementers elsewhere [11,26-27]. The costs of 254 
equipment maintenance, biomedical support, module re-calibrations and backup power supplies 255 
need to be incorporated within program budgets. Ensuring appropriate supply chains of cartridges 256 
and transport of patient sputum samples to Xpert testing sites are also probable challenges for 257 
large-scale implementers.  258 
An important limitation of the study was that we were unable to determine as to what fraction of 259 
the additionality in DR-TB cases is attributable to the implementation of Xpert testing relative to 260 
the active case finding efforts in the project. As laboratory-level data was unavailable, it was not 261 
possible to ascertain the additional increase in testing for Xpert through active case-finding or to 262 
analyze the differences in yield of Rif-resistance in new versus retreatment cases. The study was 263 
conducted in a major urban center and may not be generalizable to rural settings where yield may 264 
be lower due to lower patient volumes and underdeveloped laboratory facilities.   265 
 266 
Conclusion: 267 
This study describes a multi-faceted scale-up of Xpert testing in public and private sectors in 268 
Karachi, Pakistan. An increase in the case-notifications for DR-TB were observed, relative to the 269 
historical trends supporting existing evidence from other programmatic settings in high DR-TB 270 
burden countries. A high proportion of those identified with Rif-resistance were initiated on 271 
second line treatment under the project. Further scale up of Xpert testing needs to take into 272 
account the most appropriate diagnostic algorithms weighed against cost implications, and 273 
ensure appropriate technical and operational support for effective program delivery.   274 
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Figures: 400 
Figure 1: TB screening and Xpert MTB/RIF testing results 401 
Overview of Xpert MTB/RIF testing and TB case detection as part of the TBXpert initiative, 402 
from July 2013 to June 2015, in Karachi, Pakistan 403 
 404 
Figure 2: DR-TB case notifications (pre-and post-intervention) 405 
 DR-TB case notifications trend during intervention period and forecasted baseline trend (in the 406 
absence of any intervention), from July 2013 to June 2015, in Karachi, Pakistan 407 
 408 
Figure 3: Proportion of newly diagnosed cases among all DR-TB cases 409 
Proportion of newly diagnosed cases among all DR-TB cases, from July 2013 to June 2015, 410 
Karachi, Pakistan 411 
 412 
7: Factors contributing to low enrollment of MDR-TB patients in treatment programs 413 
Illustration of factors that have historically contributed to low enrollment of MDR-TB patients in 414 
treatment programs in Pakistan 415 
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